These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7597435)

  • 1. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
    Keren-Rosenberg S; Muggia FM
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S26-9. PubMed ID: 9071337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Smith DC; Pienta KJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
    Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
    Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.